Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Citi
Chubb
Harvard Business School
UBS
Daiichi Sankyo
Cerilliant
Merck
Mallinckrodt
Accenture

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,265,119

« Back to Dashboard

Which drugs does patent 7,265,119 protect, and when does it expire?

Patent 7,265,119 protects CHANTIX and is included in one NDA.

This patent has fifty-seven patent family members in forty-seven countries.
Summary for Patent: 7,265,119
Title:Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4.9]-hexadeca-2(11),3,5,7- ,9-pentaene and pharmaceutical compositions thereof
Abstract:The present invention is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]-hexadeca-2(11),3,5,7- ,9-pentaene: ##STR00001## and pharmaceutical compositions thereof. The present invention in particular is directed to the L-tartrate salt, and further to the various polymorphs of the L-tartrate salt, including two distinct anhydrous polymorphs (referred to herein as Forms A and B) and a hydrate polymorph (referred to herein as Form C). In addition, the present invention is also directed to the D-tartrate salt of 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]-hexadeca-2(11),3,5,7- ,9-pentaene and the various polymorphs thereof; as well as the D,L-tartrate salt thereof and its polymorphs, and the meso-tartrate salt thereof and its polymorphs.
Inventor(s): Bogle; David E. (Jewett City, CT), Williams; Glenn R. (Oaksville, CA), Rose; Peter R. (Ledyard, CT)
Assignee: Pfizer Inc (New York, NY)
Application Number:11/069,724
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,265,119

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer Inc CHANTIX varenicline tartrate TABLET;ORAL 021928-001 May 10, 2006 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y AID TO SMOKING CESSATION ➤ Try a Free Trial
Pfizer Inc CHANTIX varenicline tartrate TABLET;ORAL 021928-002 May 10, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y AID TO SMOKING CESSATION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,265,119

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,890,927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,265,119

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 60205742 ➤ Try a Free Trial
Denmark 1392307 ➤ Try a Free Trial
Dominican Republic P2002000392 ➤ Try a Free Trial
Eurasian Patent Organization 200301121 ➤ Try a Free Trial
Eurasian Patent Organization 005528 ➤ Try a Free Trial
Ecuador SP034850 ➤ Try a Free Trial
Ecuador SP034849 ➤ Try a Free Trial
Estonia 200300556 ➤ Try a Free Trial
Estonia 05441 ➤ Try a Free Trial
Egypt 24228 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
McKinsey
Covington
Julphar
UBS
Moodys
US Army
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot